HK1028981A1 - Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of these proteins - Google Patents
Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of these proteinsInfo
- Publication number
- HK1028981A1 HK1028981A1 HK00107543A HK00107543A HK1028981A1 HK 1028981 A1 HK1028981 A1 HK 1028981A1 HK 00107543 A HK00107543 A HK 00107543A HK 00107543 A HK00107543 A HK 00107543A HK 1028981 A1 HK1028981 A1 HK 1028981A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- hpv
- compositions
- cells
- antigen
- stress protein
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 7
- 102000036639 antigens Human genes 0.000 title abstract 7
- 108091007433 antigens Proteins 0.000 title abstract 7
- 102000002812 Heat-Shock Proteins Human genes 0.000 title abstract 5
- 108010004889 Heat-Shock Proteins Proteins 0.000 title abstract 5
- 230000028993 immune response Effects 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000013604 expression vector Substances 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 241000701806 Human papillomavirus Species 0.000 abstract 9
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000004927 fusion Effects 0.000 abstract 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 230000036755 cellular response Effects 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
- 230000001461 cytolytic effect Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6043—Heat shock proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5483597P | 1997-08-05 | 1997-08-05 | |
PCT/CA1998/000246 WO1999007860A1 (en) | 1997-08-05 | 1998-03-20 | Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of these proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1028981A1 true HK1028981A1 (en) | 2001-03-16 |
Family
ID=21993829
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK00107543A HK1028981A1 (en) | 1997-08-05 | 2000-11-24 | Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of these proteins |
HK04101103A HK1058367A1 (en) | 1997-08-05 | 2004-02-16 | Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of thes proteins |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK04101103A HK1058367A1 (en) | 1997-08-05 | 2004-02-16 | Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of thes proteins |
Country Status (19)
Country | Link |
---|---|
US (4) | US6524825B1 (ko) |
EP (1) | EP1002110B2 (ko) |
JP (2) | JP4198315B2 (ko) |
KR (2) | KR20060111731A (ko) |
CN (3) | CN100489105C (ko) |
AT (2) | ATE231917T1 (ko) |
AU (1) | AU6492498A (ko) |
BR (1) | BR9812272A (ko) |
CA (1) | CA2298840A1 (ko) |
DE (2) | DE69834671T2 (ko) |
DK (1) | DK1002110T3 (ko) |
ES (2) | ES2191929T3 (ko) |
HK (2) | HK1028981A1 (ko) |
HU (1) | HUP0003601A3 (ko) |
IL (1) | IL134341A0 (ko) |
NZ (3) | NZ522653A (ko) |
PL (1) | PL196805B1 (ko) |
PT (2) | PT1336621E (ko) |
WO (1) | WO1999007860A1 (ko) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0700445T3 (da) | 1993-06-04 | 2002-05-13 | Whitehead Biomedical Inst | Stressproteiner og anvendelser deraf |
US7157089B1 (en) | 1996-11-26 | 2007-01-02 | Stressgen Biotechnologies Corporation | Immune responses using compositions containing stress proteins |
IL134341A0 (en) * | 1997-08-05 | 2001-04-30 | Stressgen Biotechnologies Corp | Compositions for inducing an immune response containing an hpv protein antigen |
AU5926700A (en) | 1999-07-08 | 2001-01-30 | Stressgen Biotechnologies Corporation | Induction of a th1-like response in vitro |
US20050226890A1 (en) * | 1999-08-12 | 2005-10-13 | Cohen David I | Tat-based vaccine compositions and methods of making and using same |
AUPQ233799A0 (en) * | 1999-08-19 | 1999-09-09 | Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales | Recombinant sub-unit vaccine |
US20050100928A1 (en) * | 1999-09-16 | 2005-05-12 | Zycos Inc., A Delaware Corporation | Nucleic acids encoding polyepitope polypeptides |
AU7743100A (en) * | 1999-09-30 | 2001-04-30 | Corixa Corporation | Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
US7378096B2 (en) | 1999-09-30 | 2008-05-27 | Health Research, Inc. | Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
CA2388045C (en) * | 1999-10-20 | 2014-02-11 | Tzyy-Choou Wu | Nucleic acid immunogenic compositions encoding hsp-antigen chimera |
US8128922B2 (en) | 1999-10-20 | 2012-03-06 | Johns Hopkins University | Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen |
WO2001051081A1 (en) | 2000-01-14 | 2001-07-19 | Whitehead Institute For Biomedical Research | In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent |
AU2001261515A1 (en) * | 2000-05-12 | 2001-11-26 | The Regents Of The University Of California | Treatment of human papillomavirus (hpv)-infected cells |
AU2001271449B2 (en) | 2000-06-26 | 2006-08-24 | Nventa Biopharmaceuticals Corporation | Human papilloma virus treatment |
WO2002012281A2 (en) | 2000-08-03 | 2002-02-14 | Johns Hopkins University | Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen |
US20080044435A1 (en) * | 2004-03-16 | 2008-02-21 | Cohen David I | Tat-Based Tolerogen Compositions and Methods of Making and Using Same |
WO2006033665A1 (en) * | 2004-03-16 | 2006-03-30 | Inist Inc. | Tat-based vaccine compositions and methods of making and using same |
CN100400099C (zh) * | 2001-01-04 | 2008-07-09 | 北京迪威华宇生物技术有限公司 | 预防和治疗人前列腺癌的重组蛋白疫苗 |
WO2002061113A2 (en) * | 2001-02-01 | 2002-08-08 | The Johns Hopkins University | Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation |
BR0206995A (pt) | 2001-02-05 | 2005-08-16 | Stressgen Biotechnologies Corp | Tratamento do vìrus da hepatite b |
AUPR446801A0 (en) | 2001-04-18 | 2001-05-17 | University Of Queensland, The | Novel compositions and uses therefor |
KR100785397B1 (ko) * | 2001-06-28 | 2007-12-13 | 아피메즈 주식회사 | 인체 파필로마 바이러스 유사 입자를 생산하는 재조합아데노바이러스 벡터 및 자궁경부암 생백신 |
KR100474114B1 (ko) * | 2001-12-24 | 2005-03-08 | 대한민국 | 소 타일레리아병에 대한 면역원성이 증진된 융합단백질, 및 그의 제조방법 및 용도 |
US7763259B2 (en) * | 2003-01-10 | 2010-07-27 | The Regents Of The University Of Colorado | Therapeutic and prophylactic vaccine for the treatment and prevention of papillomavirus infection |
US7211257B2 (en) * | 2003-02-10 | 2007-05-01 | Rosalind Franklin University Of Medicine And Science | Methods for inducing apoptosis in ovarian carcinoma cells using an anti-regeneration and tolerance factor antibody |
WO2004098526A2 (en) | 2003-05-05 | 2004-11-18 | Johns Hopkins University | Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein |
CN103074316B (zh) | 2003-05-22 | 2015-10-21 | 美国弗劳恩霍夫股份有限公司 | 用于表达、传递及纯化目标多肽的重组载体分子 |
WO2005028496A2 (en) | 2003-09-12 | 2005-03-31 | Antigenics, Inc. | Vaccine for treatment and prevention of herpes simplex virus infection |
US7304139B2 (en) * | 2003-10-28 | 2007-12-04 | University Of Florida Research Foundation, Inc. | Polynucleotides and polypeptides of Anaplasma phagocytophilum and methods of using the same |
FR2868781B1 (fr) * | 2004-04-13 | 2008-02-22 | Immutep | Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations |
CN1727362B (zh) * | 2004-07-30 | 2010-12-01 | 中国人民解放军第二军医大学 | 癌胚抗原阳性肿瘤治疗性疫苗的制备及应用 |
CN1769298B (zh) * | 2004-11-05 | 2010-04-07 | 中国人民解放军军事医学科学院生物工程研究所 | 一种具有抗肿瘤作用的融合蛋白及其编码基因与应用 |
CA2594040A1 (en) | 2005-01-06 | 2006-07-13 | The Johns Hopkins University | Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines |
CN1299769C (zh) * | 2005-01-31 | 2007-02-14 | 中国医学科学院肿瘤医院肿瘤研究所 | 人乳头瘤病毒和热休克蛋白重组蛋白疫苗及其用途 |
US7807369B2 (en) * | 2005-04-27 | 2010-10-05 | Leiden University Medical Center | Methods and means for the treatment of HPV induced intraepithelial neoplasia |
EP1919504B1 (en) | 2005-08-03 | 2013-10-16 | iBio, Inc. | Antibody to bacillus anthracis protective antigen |
US7951384B2 (en) * | 2005-08-05 | 2011-05-31 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
US9216212B2 (en) | 2005-08-05 | 2015-12-22 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
WO2007038083A2 (en) * | 2005-09-21 | 2007-04-05 | New York University | Heat shock proteins from mycobacterium leprae and uses thereof |
US7972776B2 (en) * | 2005-11-15 | 2011-07-05 | Oncohealth Corporation | Protein chips for HPV detection |
US7732166B2 (en) * | 2005-11-15 | 2010-06-08 | Oncohealth Corporation | Detection method for human pappilomavirus (HPV) and its application in cervical cancer |
US8277816B2 (en) * | 2006-02-13 | 2012-10-02 | Fraunhofer Usa, Inc. | Bacillus anthracis antigens, vaccine compositions, and related methods |
KR20080106433A (ko) | 2006-02-13 | 2008-12-05 | 프라운호퍼 유에스에이, 인코포레이티드 | 인플루엔자 항원, 백신 조성물 및 관련 방법 |
KR20080106434A (ko) * | 2006-02-13 | 2008-12-05 | 프라운호퍼 유에스에이, 인코포레이티드 | Hpv 항원, 백신 조성물 및 관련된 방법 |
KR20090021295A (ko) * | 2006-05-31 | 2009-03-02 | 엔벤타 바이오파마슈티칼스 코퍼레이션 | 생물활성 정제된 HspE7 조성물 |
CN100410382C (zh) * | 2006-08-18 | 2008-08-13 | 上海交通大学医学院 | 一种可诱生细胞免疫应答的共表达载体和真核表达载体 |
US20100003704A1 (en) * | 2008-06-13 | 2010-01-07 | Shuling Cheng | IN SITU detection of early stages and late stages HPV infection |
US8968995B2 (en) * | 2008-11-12 | 2015-03-03 | Oncohealth Corp. | Detection, screening, and diagnosis of HPV-associated cancers |
JP2010514698A (ja) * | 2006-12-22 | 2010-05-06 | ダウ・アグロサイエンス・エル・エル・シー | 植物によって製造されるウエストナイルウイルス(wnv)ワクチン、ベクターおよび植物コドン最適化配列 |
US9085638B2 (en) | 2007-03-07 | 2015-07-21 | The Johns Hopkins University | DNA vaccine enhancement with MHC class II activators |
US20080311145A1 (en) * | 2007-04-04 | 2008-12-18 | Specigen, Inc. | Protein cage immunotherapeutics |
WO2008134643A2 (en) * | 2007-04-28 | 2008-11-06 | Fraunhofer Usa, Inc. | Trypanosoma antigens, vaccine compositions, and related methods |
CN101952320B (zh) * | 2007-06-18 | 2013-08-14 | 上海泽润安珂生物制药有限公司 | 具有免疫原性的物质 |
US8088392B2 (en) * | 2007-06-18 | 2012-01-03 | Yunxu Cao | Capsid proteins and uses therefore |
CA2692933C (en) | 2007-07-11 | 2016-10-18 | Fraunhofer Usa, Inc. | Yersinia pestis antigens, vaccine compositions, and related methods |
CU23674A1 (es) | 2007-07-31 | 2011-05-27 | Ct Ingenieria Genetica Biotech | Péptidos penetradores a células fusionados a una biomolécula con acción terapéutica |
BRPI0815662A2 (pt) * | 2007-08-20 | 2016-09-27 | Fraunhofer Usa Inc | vacinas, antígenos, composições, e métodos profilácticos e terapêuticos para gripe |
WO2009127988A1 (en) * | 2008-04-16 | 2009-10-22 | Universite De Lausanne | Method and vaccine for optimizing the specific immune responses |
US9527906B2 (en) * | 2008-04-18 | 2016-12-27 | The General Hospital Corporation | Immunotherapies employing self-assembling vaccines |
US8734803B2 (en) | 2008-09-28 | 2014-05-27 | Ibio Inc. | Humanized neuraminidase antibody and methods of use thereof |
US8580270B2 (en) * | 2008-09-30 | 2013-11-12 | University Of Massachusetts | Respiratory synctial virus (RSV) sequences for protein expression and vaccines |
ES2432863T3 (es) | 2009-03-23 | 2013-12-05 | Pin Pharma, Inc. | Tratamiento del cáncer con polipéptidos inmunoestimuladores derivados de Tat del VIH |
JP2012526286A (ja) | 2009-05-07 | 2012-10-25 | オンコヘルス コーポレーション | ヒトパピローマウイルス(hpv)およびhpv関連癌の初期段階および後期段階の検出、スクリーニング、および診断のための高度または≧cin2の同定 |
EP2483307A1 (en) | 2009-09-29 | 2012-08-08 | Fraunhofer USA, Inc. | Influenza hemagglutinin antibodies, compositions, and related methods |
JP5819851B2 (ja) | 2010-01-08 | 2015-11-24 | オンコヘルス コーポレーション | Hpv関連の癌の治療及びスクリーニングのための細胞に基づいた高処理能力hpv免疫アッセイ |
CA2793838C (en) | 2010-03-19 | 2019-09-17 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Integrin interaction inhibitors for the treatment of cancer |
US20140155469A1 (en) | 2011-04-19 | 2014-06-05 | The Research Foundation Of State University Of New York | Adeno-associated-virus rep sequences, vectors and viruses |
EP2734231A1 (en) * | 2011-07-21 | 2014-05-28 | Biotech Tools S.A. | Dosage of dnak |
WO2014164727A1 (en) | 2013-03-12 | 2014-10-09 | Wisconsin Alumni Research Foundation | A method of treating fungal infection |
RU2537233C2 (ru) * | 2013-03-26 | 2014-12-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кабардино-Балкарский государственный университет им. Х.М. Бербекова" (КБГУ) | Применение комплекса антиоксидантных витаминов и аминокислот в качестве дополнения к стандартным методам терапии и способ лечения папилломавирус-ассоциированных предраковых заболеваний шейки матки и профилактики канцерогенеза при папилломавирусной инфекции |
CA2926221A1 (en) | 2013-10-04 | 2015-04-09 | Pin Pharma, Inc. | Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment |
FR3011850B1 (fr) * | 2013-10-15 | 2018-04-06 | Cfl Biotech | Vaccin therapeutique contre le cancer a base de proteines de stress rendues immunogenes |
KR20170121301A (ko) * | 2015-03-18 | 2017-11-01 | 옴니사이트 | 변형된 알파 바이러스 표면 당 단백질 및 종양-관련 항원을 포함하는 융합 단백질 및 이의 방법 |
US10561723B2 (en) | 2015-07-21 | 2020-02-18 | Theodore C. Marbley | Treatment and prevention of anal conditions |
CN108484776B (zh) * | 2018-03-19 | 2019-11-05 | 首都医科大学附属北京朝阳医院 | 一种融合蛋白、制备方法及其应用 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US550405A (en) * | 1895-11-26 | Island | ||
GB8404280D0 (en) | 1984-02-17 | 1984-03-21 | Stanford J L | Biological preparations |
IL71683A0 (en) | 1984-04-27 | 1984-09-30 | Yeda Res & Dev | Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria |
US4906742A (en) | 1986-07-31 | 1990-03-06 | Whitehead Institute For Biomedical Research | Encoding antigens of M. Leprae |
US6007806A (en) | 1986-08-13 | 1999-12-28 | Transgene S.A. | Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor |
NL8701163A (nl) | 1986-09-09 | 1988-04-05 | Nederlanden Staat | Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits. |
WO1988005823A2 (en) | 1987-02-02 | 1988-08-11 | Whitehead Institute For Biomedical Research | Mycobacterium tuberculosis genes encoding protein antigens |
US4952395A (en) | 1987-02-26 | 1990-08-28 | Scripps Clinic And Research Foundation | Mycobacterial recombinants and peptides |
US5504005A (en) | 1987-03-02 | 1996-04-02 | Albert Einstein College Of Medicine Of Yeshiva University | Recombinant mycobacterial vaccine |
WO1990015873A1 (en) | 1989-06-19 | 1990-12-27 | Whitehead Institute For Biomedical Research | Vector-mediated genomic insertion and expression of dna in bcg |
US4918166A (en) | 1987-04-10 | 1990-04-17 | Oxford Gene Systems Limited | Particulate hybrid HIV antigens |
NL8703107A (nl) | 1987-12-22 | 1989-07-17 | Nederlanden Staat | Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten. |
CA1338778C (en) | 1988-06-15 | 1996-12-10 | Richard A. Young | Stress proteins and uses therefor |
US5114844A (en) | 1989-03-14 | 1992-05-19 | Yeda Research And Development Co., Ltd. | Diagnosis and treatment of insulin dependent diabetes mellitus |
GB8919321D0 (en) | 1989-08-25 | 1989-10-11 | Univ London | Treatment of chronic inflammatory conditions |
GB9007194D0 (en) | 1990-03-30 | 1990-05-30 | Wellcome Found | Live vaccines |
US5348945A (en) | 1990-04-06 | 1994-09-20 | Wake Forest University | Method of treatment with hsp70 |
GB9024320D0 (en) | 1990-11-08 | 1990-12-19 | Univ London | Treatment of uveitis |
AU660430B2 (en) | 1990-11-08 | 1995-06-29 | Stanford Rook Limited | Mycobacterium as adjuvant for antigens |
GB2251186A (en) | 1990-12-04 | 1992-07-01 | Randall Neal Gatz | Polypeptide for use in treatment of autoimmune disease |
IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
WO1993022343A1 (en) | 1992-05-01 | 1993-11-11 | The Rockfeller University | Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom |
GB9211736D0 (en) | 1992-06-03 | 1992-07-15 | Univ Cardiff | Allergic treatment |
IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
US5736146A (en) | 1992-07-30 | 1998-04-07 | Yeda Research And Development Co. Ltd. | Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them |
JP2541081B2 (ja) * | 1992-08-28 | 1996-10-09 | 日本電気株式会社 | バイオセンサ及びバイオセンサの製造・使用方法 |
DK0700445T3 (da) | 1993-06-04 | 2002-05-13 | Whitehead Biomedical Inst | Stressproteiner og anvendelser deraf |
US5762939A (en) | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
US5750119A (en) | 1994-01-13 | 1998-05-12 | Mount Sinai School Of Medicine Of The City University Of New York | Immunotherapeutic stress protein-peptide complexes against cancer |
US5997873A (en) | 1994-01-13 | 1999-12-07 | Mount Sinai School Of Medicine Of The City University Of New York | Method of preparation of heat shock protein 70-peptide complexes |
US5961979A (en) | 1994-03-16 | 1999-10-05 | Mount Sinai School Of Medicine Of The City University Of New York | Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
IL109790A0 (en) * | 1994-05-25 | 1994-08-26 | Yeda Res & Dev | Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines |
GB9419979D0 (en) | 1994-10-04 | 1994-11-16 | Medeva Holdings Bv | Vaccine compositions |
AUPN015794A0 (en) * | 1994-12-20 | 1995-01-19 | Csl Limited | Variants of human papilloma virus antigens |
EP0812358A1 (en) * | 1995-02-24 | 1997-12-17 | Cantab Pharmaceuticals Research Limited | Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation |
AU724399B2 (en) * | 1995-08-18 | 2000-09-21 | Sloan-Kettering Institute For Cancer Research | Heat shock protein-based vaccines and immunotherapies |
US5985270A (en) | 1995-09-13 | 1999-11-16 | Fordham University | Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes |
US5837251A (en) | 1995-09-13 | 1998-11-17 | Fordham University | Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases |
US5935576A (en) | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
WO1997010000A1 (en) | 1995-09-13 | 1997-03-20 | Fordham University | Therapeutic and prophylactic methods using heat shock proteins |
WO1997026910A2 (de) | 1996-01-27 | 1997-07-31 | Max-Delbrück-Centrum für Molekulare Medizin | Tumorimpfstoff für die immuntherapie von malignen tumoren |
US6130087A (en) | 1996-10-07 | 2000-10-10 | Fordham University | Methods for generating cytotoxic T cells in vitro |
DK0941315T3 (da) | 1996-11-26 | 2006-05-15 | Stressgen Biotechnologies Corp | Fusionsproteiner indeholdende stressproteiner til induktion af immunreaktioner |
US5830464A (en) | 1997-02-07 | 1998-11-03 | Fordham University | Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy |
US6017540A (en) | 1997-02-07 | 2000-01-25 | Fordham University | Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes |
CA2282426A1 (en) | 1997-02-18 | 1998-08-20 | The Whitehead Institute For Biomedical Research | Use of heat shock proteins to deliver moieties into cells |
IL134341A0 (en) * | 1997-08-05 | 2001-04-30 | Stressgen Biotechnologies Corp | Compositions for inducing an immune response containing an hpv protein antigen |
US6007821A (en) | 1997-10-16 | 1999-12-28 | Fordham University | Method and compositions for the treatment of autoimmune disease using heat shock proteins |
US5948646A (en) | 1997-12-11 | 1999-09-07 | Fordham University | Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes |
AU5926700A (en) * | 1999-07-08 | 2001-01-30 | Stressgen Biotechnologies Corporation | Induction of a th1-like response in vitro |
-
1998
- 1998-03-20 IL IL13434198A patent/IL134341A0/xx unknown
- 1998-03-20 CN CNB988091216A patent/CN100489105C/zh not_active Expired - Fee Related
- 1998-03-20 PT PT03001726T patent/PT1336621E/pt unknown
- 1998-03-20 PL PL338478A patent/PL196805B1/pl not_active IP Right Cessation
- 1998-03-20 NZ NZ522653A patent/NZ522653A/en unknown
- 1998-03-20 AT AT98910557T patent/ATE231917T1/de not_active IP Right Cessation
- 1998-03-20 NZ NZ538399A patent/NZ538399A/en unknown
- 1998-03-20 PT PT98910557T patent/PT1002110E/pt unknown
- 1998-03-20 CN CNA2006101055473A patent/CN1915425A/zh active Pending
- 1998-03-20 HU HU0003601A patent/HUP0003601A3/hu unknown
- 1998-03-20 DE DE1998634671 patent/DE69834671T2/de not_active Expired - Lifetime
- 1998-03-20 WO PCT/CA1998/000246 patent/WO1999007860A1/en not_active Application Discontinuation
- 1998-03-20 DE DE1998611087 patent/DE69811087T2/de not_active Expired - Lifetime
- 1998-03-20 KR KR1020067019653A patent/KR20060111731A/ko not_active Application Discontinuation
- 1998-03-20 ES ES98910557T patent/ES2191929T3/es not_active Expired - Lifetime
- 1998-03-20 AT AT03001726T patent/ATE327259T1/de not_active IP Right Cessation
- 1998-03-20 KR KR1020007001231A patent/KR100843109B1/ko not_active IP Right Cessation
- 1998-03-20 DK DK98910557T patent/DK1002110T3/da active
- 1998-03-20 NZ NZ50256898A patent/NZ502568A/xx unknown
- 1998-03-20 CA CA 2298840 patent/CA2298840A1/en not_active Abandoned
- 1998-03-20 JP JP2000506343A patent/JP4198315B2/ja not_active Expired - Fee Related
- 1998-03-20 AU AU64924/98A patent/AU6492498A/en not_active Abandoned
- 1998-03-20 CN CNA2005100624792A patent/CN1680451A/zh active Pending
- 1998-03-20 EP EP19980910557 patent/EP1002110B2/en not_active Expired - Lifetime
- 1998-03-20 BR BR9812272A patent/BR9812272A/pt not_active Application Discontinuation
- 1998-03-20 ES ES03001726T patent/ES2266652T3/es not_active Expired - Lifetime
-
2000
- 2000-02-04 US US09/498,918 patent/US6524825B1/en not_active Expired - Fee Related
- 2000-11-24 HK HK00107543A patent/HK1028981A1/xx not_active IP Right Cessation
-
2002
- 2002-11-07 US US10/289,760 patent/US6900035B2/en not_active Expired - Fee Related
-
2004
- 2004-02-16 HK HK04101103A patent/HK1058367A1/xx not_active IP Right Cessation
- 2004-09-10 US US10/938,695 patent/US7262014B2/en not_active Expired - Fee Related
-
2005
- 2005-07-21 JP JP2005211965A patent/JP2006001939A/ja not_active Withdrawn
-
2007
- 2007-07-26 US US11/828,900 patent/US20080050399A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1028981A1 (en) | Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of these proteins | |
ZA987591B (en) | Vaccine. | |
WO2002012281A3 (en) | Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen | |
WO2002080851A3 (en) | Chimeric vaccines | |
WO2001029233A3 (en) | Chimeric immunogenic compositions and nucleic acids encoding them | |
Sedlik et al. | Different immunogenicity but similar antitumor efficacy of two DNA vaccines coding for an antigen secreted in different membrane vesicle-associated forms | |
EP1847549A3 (en) | Papillomavirus polyprotein constructs | |
HUP0001930A2 (hu) | Módosított TNFalfa-molekulák, ilyen módosított TNFalfa-molekulákat kódoló DNS, valamint ilyen módosított TNFalfa-molekulát és DNS-t tartalmazó vakcinák | |
DK1278534T3 (da) | Fremgangsmåder og sammensætninger til svækkelse af multiplikationen af HIV-1 | |
WO2005081716A3 (en) | DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV) | |
EA200300640A1 (ru) | Фармацевтические композиции, усиливающие иммуногенность антигенов со слабой иммуногенностью | |
DK1053329T3 (da) | Rekombinant lipideret PsaA-protein, fremgangsmåder til fremstilling og anvendelse | |
GB0113798D0 (en) | Antigens and vectors for vaccination | |
WO2004062584A3 (en) | Therapeutic and prophylactic vaccine for the treatment and prevention of papillomavirus infection | |
WO2000052045A3 (en) | Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof | |
WO2002044202A3 (fr) | Peptides immunogeniques mutes derives de r9m, polynucleotides les codant et leurs usages therapeutiques | |
EP1336621A3 (en) | Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins | |
WO2001059073A3 (en) | Cytotoxic t lymphocytes activated by dendritic cell hybrids | |
WO2002051237A3 (en) | Helicobacter proteins, nucleic acids and uses thereof | |
NZ334582A (en) | Polyprotein construct of a papillomavirus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PF | Patent in force | ||
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20110320 |